Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Ficolin-1 is a soluble and cell-associated pattern recognition receptor belonging to the collectin family, characterized by a collagen-like domain and a C-terminal fibrinogen-like domain. It is primarily expressed in myeloid cells (monocytes, neutrophils) and type II alveolar epithelial cells, and released upon cellular activation. Ficolin-1 binds to acetylated and sialylated compounds on pathogens, facilitating their neutralization, opsonization, and complement system activation via the lectin pathway. It also binds IgG1 and interacts with CD43 at cell membranes. Ficolin-1 has emerging relevance as a therapeutic target and biomarker in vasculitis, Kawasaki disease, and rheumatoid arthritis due to its upregulation in these conditions and positive response to targeted therapies in preclinical models.
Inhibition of complement activation (by blocking FCN1 binding or function); Suppression of inflammatory cell activation; Promotion of cell removal via ADCC (antibody-dependent cell-mediated cytotoxicity) or CDC (complement-dependent cytotoxicity)
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Ficolin-1 (FCN1).